Looks like you’re on the US site. Choose another location to see content specific to your location
Thermo Fisher Launches Gibco VaxEvo CD 293 for Adenovirus Vaccines
Thermo Fisher Scientific has launched Gibco VaxEvo CD 293 Medium, a chemically defined, animal-origin-free cell culture medium built for adenovirus vaccine production in suspension HEK293 cells. Announced on 18 November 2026 from the company’s cell culture business, the medium is pitched for vaccine process development, scale-up and commercial manufacturing across human and animal health adenovirus platforms, including adenoviral vector and oncolytic virus applications.
In laboratory benchmarking with HEK293 cells, VaxEvo CD 293 Medium delivered average adenovirus type 5 (Ad5) titres comparable to select supplier media, with up to 5.7-fold higher titres in some comparisons. It also produced comparable or higher titres without a dedicated feed, compared against benchmark media run with their recommended feeds. The medium is available in both liquid and AGT formats across multiple package sizes, and is labelled for research use or further manufacturing rather than diagnostic or direct administration.
The commercial case rests on three dynamics. Removing the need for a separate feed simplifies upstream workflows, reduces media SKU count and cuts training burden across CDMO and biopharma process development teams. The chemically defined, animal-origin-free composition aligns with EMA and FDA preferences for modern biomanufacturing. Up to 5.7-fold titre uplift provides a tangible yield argument during process development decisions. Alex Cherkassky, vice president and general manager of Thermo Fisher’s cell culture business, framed the timing: “Manufacturing readiness begins well before a process reaches the plant.”
The commercial signal is a widening market for chemically defined, feed-free HEK293 media as adenovirus vector production scales across vaccines, oncolytic virotherapy and gene therapy delivery. Early adopter uptake in vaccine process development and CDMO settings remains the critical near-term milestone. Expect further Gibco-branded media launches targeting adjacent viral vector platforms through 2027, with manufacturing-ready positioning becoming a central commercial differentiator.
For the latest updates and in-depth insights into the world of Service Engineering, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard